Executive Management & Board of Directors
Christer Rosén, Co-Founder, CEO & Chairman of the Board
|
Originally from Halmstad, Sweden, Christer Rosén is the Primary Founder and Chairman & CEO of Jupiter Orphan Therapeutics, Inc. He is an expert in building companies with strong and dedicated people. His past business ventures include founding Effrx Pharmaceuticals as well as 10 companies in various industries. Mr. Rosén has over 19 years of pharmaceutical experience. He is one of the few individuals that has invented a pharmaceutical product Binosto, developed it, received marketing approval by FDA, EU, MENA and Asian markets and sold through distribution partners around the world. Aside from business and family, Mr. Rosén is an avid golfer. |
Jacob Uittenbogaard, Co-Founder, CFO & Board Member
|
Jacob Uittenbogaard is the Secretary/Treasurer and CFO at Jupiter Orphan Therapeutics. He is the former CFO of RJ Reynolds International as well as at Effrx Pharmaceuticals. Originally from Holland, Mr. Uittenbogaard has more than 35 years of world wide financing and operational experience. While in Holland, Mr. Uittenbogaard became an avid sailer. |
Marshall Hayward, Ph.D., Co-Founder, CSO & Board Member
|
Marshall Hayward, Ph.D. is the Chief Scientific Officer at Jupiter Orphan Therapeutics. Between 2002-2013, Dr. Hayward served as Chief Scientific Officer at Effrx Pharmaceuticals. He also served as Vice President of Business Development for Hurley Consulting Associates, LTD., a specialist pharmaceutical consulting firm, and was previously Director of New Business Development at Rhodia Pharmaceutical Ingredients. Dr. Hayward was also the Director and Vice President of Analgesics Research and Development at SmithKline Beecham (UK). He was a senior scientist in wound healing research and development at Johnson & Johnson. His pharmaceutical experience began at Ayerst Laboratories Research (later Wyeth), responsible for metabolic bone disease research. Dr. Hayward received a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign and did postdoctoral work there in molecular biology. His undergraduate degree is a B.S. (Biochemistry with High Honor) from the Honors College of Michigan State University. In total, Dr. Hayward has over 30 years of industry R&D experience. Aside from business and family, Dr. Hayward is an avid skier.
|
Dr. Claes Wahlestedt, MD, Ph.D., Co-Founder & Board Member
|
Dr. Claes Wahlestedt, MD, Ph.D. is the Consulting Chief Medical Officer and Co-Chairman of the Scientific Advisory Board at Jupiter Orphan Therapeutics. He is a native Swede, obtaining his MD and PhD degrees from Lund University. Dr. Wahlestedt is a renowned scientist throughout the pharmaceutical industry. He is presently the Leonard M. Miller Professor & Associate Dean for Therapeutic Innovation at the University of Miami Miller School of Medicine. Between 2005-2011 Dr. Wahlestedt was the founding professor and Director of Neuroscience at The Scripps Research Institute in Florida. Before that, Dr. Wahlestedt was the Professor and Department Chair at Karolinska Institute in Stockholm, Sweden from 1997-2005. He has previously been a faculty member at Cornell University Medical College as well as at McGill University. Dr. Wahlestedt has also spent more than a decade directing R&D teams for Astra-Zeneca and Pharmacia/Pfizer. Along with all of Dr. Wahlestedt's pharmaceutical ventures, he has also co-founded 3 biotech companies. Dr. Wahlestedt enjoys his off time on the golf course.
|
Shaun P. Brothers, Ph.D., Co-Founder
|
Shaun P Brothers, Ph.D. is the Consulting VP of Science Research at Jupiter Orphan Therapeutics. Dr. Brothers is presently the Associate Professor at the University of Miami and Associate Director at Center for Therapeutic Innovation. He was formerly a researcher at Scripps Research Institute in Jupiter, Florida. He previously co-founded 2 biotech companies. Dr. Brothers is an expert reviewer for molecular probes and drug discovery in neuroscience NIH study sections. |
Alison Silva, Board Member
|
Alison Silva is the President, Chief Executive Officer and a Director of Cotinga Pharmaceuticals Inc., formerly Critical Outcome Technologies, Inc. Previously, she was a co‐founder, Executive Vice President and Chief Operating Officer at Synlogic, Inc. where she lead the regulatory strategy, drug development, and operational aspects of the company’s focus on the discovery and development of engineered therapeutic probiotics. Alison is also a co‐founder of The Orphan Group, a specialty consulting company focused on assisting companies with developing and implementing their orphan drug strategy and product lifecycle management.
Alison previously held the position of Chief Operating Officer at SLA Pharma, a GI‐oncology focused biotech company, where she was responsible for heading up U.S. corporate and clinical operations for their pipeline of orphan drug candidates. Prior to joining SLA Pharma, Alison was Vice President of Drug Development at Marina Biotech through its acquisition of Cequent Pharmaceuticals in 2010, where she held the same role since 2007. Alison began her career in drug development in clinical operations with various positions at Pfizer, Massachusetts General Hospital, and the University of Massachusetts. Alison obtained her undergraduate degree from Clark University and her graduate degree from the University of Massachusetts Medical Center. |
Scientific Advisory Board
Peter Elliott, Ph.D.
|
Peter Elliott, Ph.D. is a Scientific Advisor at Jupiter Orphan Therapeutics, Inc. Mr. Elliott holds a B.Sc. in Pharmacology from London University and a Ph.D. in Psychopharmacology from Cambridge University, After post-docs at Duke, Yale and McGill, Mr. Elliott moved back to the UK to join Glaxo Group Research. During his 5 years there he led a number of CNS programs focusing on movement disorders, neurodegeneration as well as pain. Peter moved back to the USA to enter biotech at Alkermes in Cambridge, MA, as Director of Pharmacology. After that he moved on to ProScript which was acquired by LeukoSite, and ultimately Millennium. Mr. Elliott was Vice President of Pharmacology and Development during this time and was a co-developer of the multiple myeloma drug, Velcade© and PS-519 for stroke. He later moved on to join CominatoRx where he was Executive Vice President of Product Development and led the efforts resulting in 8 phase II programs in inflammation and oncology. Peter was then Senior Vice President of R&D at Sirtris Pharmaceuticals. As part of work from his teams, three SIRT1 activators entered clinical development, SRT501, SRT2104 and SRT2379. He was also an integral part of the road-show to take Sirtris public with a successful IPO in 2007, leading to it being purchased by GSK in 2008 for $720M. Subsequently, Peter has acted as a consultant to the industry.
|
Professor Li-Huei Tsai, Ph.D.
|
Professor Li- Huei Tsai, Ph.D. is a Scientific Advisor at Jupiter Orphan Therapeutics. She currently is the Director of the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology, a Picower Professor of Neuroscience, and an Associate Member of the Broad Institute. She obtained Ph.D. from University of Texas Southwestern Medical Centre in Dallas and postdoctoral training at Cold Spring Harbor Laboratories and Massachusetts General Hospital. Dr. Tsai became Assistant Professor of Pathology at Harvard Medical School and was promoted to tenure Professor at Harvard in 2002. She relocated to Massachusetts Institute of Technology in 2006. She was an Investigator of the Howard Hughes Medical Institute from 1997 to 2013. Dr. Tsai is also a Fellow of the American Association for the Advancement of Science, a member of the National Academy of Medicine, and an Academician of the Academia Sinica in Taiwan. http://www.tsailaboratory.mit.edu
|
Dr. Raymond Scott Turner, MD, Ph.D.
|
Scott Turner, MD, Ph.D. is a Scientific Advisor at Jupiter Orphan Therapeutics. He is currently the Professor of Neurology and Director of the Memory Disorders Program at Georgetown University Medical Center, Washington, DC. Previously, he was Chief of the Neurology Service at the VA Ann Arbor Healthcare System and Associate Professor and Associate Chair in the Department of Neurology, University of Michigan. Turner obtained his MD and Ph.D. degrees from Emory University, Atlanta, and completed his internship, residency, and fellowship at the University of Pennsylvania, Philadelphia. He was recruited to Georgetown in 2008. Dr. Turner has received numerous prestigious awards, including a fellowship from the Howard Hughes Medical Institute and a Paul Beeson Scholarship. Dr. Turner serves as a reviewer for granting agencies and biomedical journals, has published more than seventy peer-reviewed paper, editorials, and book chapters, as well as lectures widely. He is board-certified in Psychiatry and Neurology.
|
Business Advisors
Ulf Wiinberg
|
World-renowned pharmaceutical executive. Former President of Wyeth and CEO of Lundbeck. Presently CEO of X-VAX Technology, Inc. and on the Board and Senior Advisor of multiple companies, such as UCB, Hansa Medical (Chairman), Agenus and Alfa Laval |
Robert Roth
|
Former CFO at RJR Nabisco and has held other financial leadership positions with various divisions of Colgate-Palmolive, General Foods, GAF and PWC. Former Board Chairman of LEK Consulting and has held board positions at several other companies. |